Inhibrx Biosciences Files 8-K on Dec 16, 2025

TL;DR

Inhibrx filed an 8-K on 12/16/25 covering financials and other events.

AI Summary

Inhibrx Biosciences, Inc. filed an 8-K on December 16, 2025, to report on various events. The filing includes information on financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, formerly known as Ibex SpinCo, Inc. until January 11, 2024, is incorporated in Delaware and headquartered in La Jolla, California.

Why It Matters

This 8-K filing provides a snapshot of Inhibrx Biosciences' regulatory and financial reporting as of December 16, 2025, which is crucial for investors tracking the company's compliance and operational updates.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting current events and financial statements, not indicating any immediate material adverse changes.

Key Players & Entities

• Inhibrx Biosciences, Inc. (company) — Registrant
• Ibex SpinCo, Inc. (company) — Former company name
• 20251216 (date) — Date of report
• 11025 N. Torrey Pines Road, Suite 140 (address) — Principal Executive Offices
• LA JOLLA (city) — Principal Executive Offices City
• CA (state) — Principal Executive Offices State
• 92037 (zip_code) — Principal Executive Offices Zip Code
• (858) 795-4220 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share INBX The Nasdaq Global Market

Filing Documents

• inhibrx-20251216.htm (8-K) — 36KB
• exhibit991-pressreleasedec.htm (EX-99.1) — 15KB
• inhibrxlogo-largea.jpg (GRAPHIC) — 939KB
• 0002007919-25-000097.txt ( ) — 1472KB
• inhibrx-20251216.xsd (EX-101.SCH) — 2KB
• inhibrx-20251216_lab.xml (EX-101.LAB) — 23KB
• inhibrx-20251216_pre.xml (EX-101.PRE) — 13KB
• inhibrx-20251216_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 16, 2025, Inhibrx Biosciences, Inc. ("Inhibrx") issued a press release announcing (i) an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda and (ii) a brief progress update on the expansion cohorts investigating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma, as discussed in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Other Events

Item 8.01. Other Events. On December 16, 2025, Inhibrx announced (i) an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda and (ii) a brief progress update on the expansion cohorts investigating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma. INBRX-106 Inhibrx has recruited 46 of the 60 patients in the randomized Phase 2 portion of the Phase 2/3 clinical trial evaluating INBRX-106 in combination with Keytruda versus Keytruda as a first-line treatment for patients with unresectable or metastatic HNSCC. Inhibrx expects to complete enrollment in the Phase 2 portion of the trial during the first quarter of 2026. This trial is recruiting patients who have not received prior systemic therapy for unresectable or metastatic HNSCC and have tumor PD-L1 CPS expression equal to or greater than 20. Patients are randomized one to one to either INBRX-106 in combination with Keytruda or Keytruda. The primary endpoint of the Phase 2 portion of this trial is overall response rate, supported by secondary endpoints of duration of response, progression free survival and safety. In November 2025, Inhibrx completed enrollment of the Phase 1/2 trial evaluating 34 patients in checkpoint inhibitor refractory or relapsed NSCLC in combination with Keytruda. Primary endpoints for this cohort are objective response rate, disease control rate, duration of response and safety. The current datasets for both HNSCC and NSCLC lack sufficient maturity to support an interpretation and conclusion on the viability of this program. Inhibrx expects that in the second half of 2026, the data

Forward-Looking Statements

Forward-Looking Statements Inhibrx cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx's judgments and beliefs regarding the strength of Inhibrx's pipeline;

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release issued by Inhibrx Biosciences, Inc. on Decemb er 16 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 16, 2025 INHIBRX BIOSCIENCES, INC. By: /s/ Kelly Deck Name: Kelly Deck Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR